Precigen’s Q2 2024 results: below expectations

Precigen (NASDAQ:PGEN) Q2 2024 Results

Key Financial Results

All numbers shown in the chart above are for the last 12 months (TTM)

Precigen’s revenues and profits fall short of expectations

Revenue was 44% below analyst estimates. Earnings per share (EPS) was also 140% below analyst estimates.

Revenues are forecast to grow at an average annual rate of 57% over the next three years, while in the US the biotech industry is forecast to grow at 23%.

Efficiency American biotechnology industry.

The company’s shares are down 16% from the previous week.

Risk analysis

Don’t forget that there may still be risks. For example, we have identified 3 warning signs for Precigen that you should know about.

Have an opinion on this article? Concerned about the content? Contact us with us directly. You can also email us at editorial-team (at) simplywallst.com.

This Simply Wall St article is for general information purposes only. Our commentary is based solely on historical data and analyst forecasts, and is based on an objective methodology. Our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or your financial situation. Our goal is to provide you with long-term, focused analysis based on fundamental data. Please note that our analysis may not reflect the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.